58 29. Yeh IT, Martin MA, Robetorye RS, Bolla AR, McCaskill C, Shah RK, Gorre ME, Mohammed MS, Gunn SR (2009) Clinical vali- dation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol 22(9):1169–1175 30. Marchio C, Lambros MB, Gugliotta P, Di Cantogno LV, Botta C, Pasini B, Tan DS, Mackay A, Fenwick K, Tamber N, Bussolati G, Ashworth A, Reis-Filho JS, Sapino A (2009) Does chromosome 17 centromere copy number predict polysomy in breast cancer? A ﬂuorescence in situ hybridization and microarray-based CGH analysis. J Pathol 219(1):16–24. doi:10.1002/path.2574 31. Kwek SS, Roy R, Zhou H, Climent J, Martinez-Climent JA, Fridlyand J, Albertson DG (2009) Co-ampliﬁed genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis. Oncogene 28(17):1892–1903 32. van Diest PJ, Michalides RJ, Jannink L, van der Valk P, Peterse HL, de Jong JS, Meijer CJ, Baak JP (1997) Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol 150(2):705–711 33. Seshadri R, Lee CS, Hui R, McCaul K, Horsfall DJ, Sutherland RL (1996) Cyclin DI ampliﬁcation is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res 2(7):1177–1184 34. Elsheikh S, Green AR, Aleskandarany MA, Grainge M, Paish CE, Lambros MB, Reis-Filho JS, Ellis IO (2008) CCND1 ampliﬁcation and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat 109(2):325–335. doi:10.1007/s10549-007-9659-8 35. Kirkegaard T, Nielsen KV, Jensen LB, Campbell FM, Muller S, Tovey SM, Brown S, Cooke TG, Bartlett JM (2008) Genetic alterations of CCND1 and EMSY in breast cancers. Histopa- thology 52(6):698–705 36. Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, Li F, Reiss M, Au JL, Haffty BG, Kang Y (2009) MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 15(1):9–20. doi:S1535-6108(08)00379-6 37. Hynes NE, Dey JH (2010) Potential for targeting the ﬁbroblast growth factor receptors in breast cancer. Cancer Res 70(13): 5199–5202. doi:0008-5472.CAN-10-0918 38. Mazzocca A, Coppari R, De Franco R, Cho JY, Libermann TA, Pinzani M, Toker A (2005) A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res 65(11):4728–4738 39. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10(6):529–541. doi:S1535-6108(06)00315-1 40. Albertson DG (2008) Conﬂicting evidence on the frequency of ESR1 ampliﬁcation in breast cancer. Nat Genet 40(7):821–822 41. Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, Al-Kuraya K, Janicke F, Sauter G, Simon R (2007) Estrogen receptor alpha (ESR1) gene ampliﬁ- cation is frequent in breast cancer. Nat Genet 39(5):655–660 42. Moelans CB, Monsuur HN, de Pinth JH, Radersma RD, de Weger RA, van Diest PJ (2010) ESR1 ampliﬁcation is rare in breast 123 Breast Cancer Res Treat (2012) 135:49–58 cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe ampliﬁcation study. Cell Oncol. doi:02L6837051608424 43. Greten FR, Karin M (2004) The IKK/NF-kappaB activation pathway—a target for prevention and treatment of cancer. Cancer Lett 206(2):193–199. doi:10.1016/j.canlet.2003.08.029 44. Nishikawa N, Toyota M, Suzuki H, Honma T, Fujikane T, Ohmura T, Nishidate T, Ohe-Toyota M, Maruyama R, Sonoda T, Sasaki Y, Urano T, Imai K, Hirata K, Tokino T (2007) Gene ampliﬁcation and overexpression of PRDM14 in breast cancers. Cancer Res 67(20):9649–9657 45. Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin SF, Milner J, Brown LA, Hsu F, Gilks B, Nielsen T, Schulzer M, Chia S, Ragaz J, Cahn A, Linger L, Ozdag H, Cattaneo E, Jor- danova ES, Schuuring E, Yu DS, Venkitaraman A, Ponder B, Doherty A, Aparicio S, Bentley D, Theillet C, Ponting CP, Caldas C, Kouzarides T (2003) EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115(5):523–535 46. Cleton-Jansen AM (2002) E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res 4(1):5–8 47. Camilleri-Broet S, Cremer I, Marmey B, Comperat E, Viguie F, Audouin J, Rio MC, Fridman WH, Sautes-Fridman C, Regnier CH (2007) TRAF4 overexpression is a common characteristic of human carcinomas. Oncogene 26(1):142–147 48. Abdelmagid SA, Too CK (2008) Prolactin and estrogen up-regulate carboxypeptidase-d to promote nitric oxide production and survival of mcf-7 breast cancer cells. Endocrinology 149(10):4821–4828 49. Zhang D, Jiang P, Xu Q, Zhang X (2011) Arginine and glutamate- rich 1 (ARGLU1) interacts with mediator subunit 1 (MED1) and is required for estrogen receptor-mediated gene transcription and breast cancer cell growth. J Biol Chem 286(20):17746–17754 50. Gonzalez S, Klatt P, Delgado S, Conde E, Lopez-Rios F, San- chez-Cespedes M, Mendez J, Antequera F, Serrano M (2006) Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature 440(7084):702–706 51. Ikeda H, Taira N, Hara F, Fujita T, Yamamoto H, Soh J, Toyooka S, Nogami T, Shien T, Doihara H, Miyoshi S (2010) The estrogen receptor inﬂuences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulve- strant downregulates MAPT and increases the sensitivity to tax- ane in breast cancer cells. Breast Cancer Res 12(3):R43 52. Davis LM, Harris C, Tang L, Doherty P, Hraber P, Sakai Y, Bocklage T, Doeden K, Hall B, Alsobrook J, Rabinowitz I, Williams TM, Hozier J (2007) Ampliﬁcation patterns of three genomic regions predict distant recurrence in breast carcinoma. J Mol Diagn 9(3):327–336. doi:S1525-1578(10)60401-1 53. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS (2002) Cyclin E and survival in patients with breast cancer. N Engl J Med 347(20):1566–1575. doi:10.1056/NEJMoa021153 54. Staff S, Isola J, Jumppanen M, Tanner M (2010) Aurora-A gene is frequently ampliﬁed in basal-like breast cancer. Oncol Rep 23(2):307–312